Loading...

APC anti-mouse CD279 (PD-1) Antibody

Pricing & Availability
Clone
29F.1A12 (See other available formats)
Regulatory Status
RUO
Other Names
PD-1, Programmed Death-1
Isotype
Rat IgG2a, κ
Ave. Rating
Submit a Review
Product Citations
publications
29F.1A12 APC_033010
Con-A and IL-2 stimulated C57BL/6 splenocytes (3 days) stained with 29F.1A12 APC
  • 29F.1A12 APC_033010
    Con-A and IL-2 stimulated C57BL/6 splenocytes (3 days) stained with 29F.1A12 APC
Compare all formats See APC spectral data
Cat # Size Price Quantity Check Availability Save
135209 25 µg 113 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
135210 100 µg 296 CHF
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD279, also known as programmed death-1 (PD-1), is a 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily. PD-1 is expressed on activated splenic T and B cells and thymocytes. It is induced on activated myeloid cells as well. PD-1 is involved in lymphocyte clonal selection and peripheral tolerance through binding its ligands, B7-H1 (PD-L1) and B7-DC (PD-L2). It has been reported that PD-1 and PD-L1 interactions are critical to positive selection and play a role in shaping the T cell repertoire. PD-L1 negative costimulation is essential for prolonged survival of intratesticular islet allografts.

Product Details
Technical Data Sheet (pdf)

Product Details

Verified Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
PD-1 cDNA followed by PD-1-Ig fusion protein
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with APC under optimal conditions.
Concentration
0.2 mg/ml
Storage & Handling
The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested
Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.

Excitation Laser
Red Laser (633 nm)
Application Notes

Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen tissue3, in vivo blocking of PD-1 binding to its ligands2,3, and spatial biology (IBEX)5,6.

Application References

(PubMed link indicates BioLegend citation)
  1. Good-Jacobson KL, et al. 2010. Nat. Immunol. 11:535. (FC) PubMed
  2. Lázár-Molnár E, et al. 2008. Proc. Natl. Acad. Sci. USA 105:2658. (Block)
  3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706. (FC, IHC, Block)
  4. Tobias J, et al. 2020. Front Immunol. 11:895 (FC, ELISA) PubMed
  5. Radtke AJ, et al. 2020. Proc Natl Acad Sci U S A. 117:33455-65. (SB) PubMed
  6. Radtke AJ, et al. 2022. Nat Protoc. 17:378-401. (SB) PubMed
Product Citations
  1. Wu J et al. 2017. Immunity. 47(6):1114-1128 . PubMed
  2. Saha D et al. 2017. Cancer cell. 32(2):253-267 . PubMed
  3. Qi Z, et al. 2022. Nat Commun. 13:182. PubMed
  4. Wu Q, et al. 2021. Cancer Commun (Lond). Online ahead of prin. PubMed
  5. Xie A et al. 2017. Endocrinology. 158(10):3140-3151 . PubMed
  6. Zhou J, et al. 2019. Immunity. 50:403. PubMed
  7. Lino AC et al. 2018. Immunity. 49(1):120-133 . PubMed
  8. Wang J, et al. 2019. Front Immunol. 9:3157. PubMed
  9. Liu QZ, et al. 2018. Front Immunol. 1.131944444. PubMed
  10. Waide ML, et al. 2020. Cell Rep. 33:108503. PubMed
  11. Smith T, et al. 2014. J Immunol. 193:3409. PubMed
  12. Almshayakhchi R, et al. 2021. Front Oncol. 11:636977. PubMed
  13. Wei JL, et al. 2021. J Immunother Cancer. 9: . PubMed
  14. Stokes J, et al. 2020. Oncoimmunology. 9:1758011. PubMed
  15. Stewart JM, et al. 2020. ACS Biomater Sci Eng. 6:5941. PubMed
  16. Cha SE, et al. 2021. Oncoimmunology. 10:1899469. PubMed
  17. Len-Letelier RA, et al. 2020. Frontiers in Immunology. 11:583382. PubMed
  18. Imani J, et al. 2021. JCI Insight. 6:. PubMed
  19. Cheng B, et al. 2022. Cancer Commun (Lond). 42:17. PubMed
  20. Lasso P, et al. 2020. Front Immunol. 584959:11. PubMed
  21. Ren Y, et al. 2022. J Immunother Cancer. 10:. PubMed
  22. Pilones KA, et al. 2020. Cancer Immunol Res. 8:1054. PubMed
  23. Habib S, et al. 2018. Infect Immun. 86:e00019. PubMed
  24. Shen M, et al. 2022. Nat Cancer. 3:60. PubMed
  25. Webb ER, et al. 2022. iScience. 25:104995. PubMed
  26. LaFleur MW, et al. 2019. Nat Commun. 10:1668. PubMed
  27. Moon S, et al. 2021. J Exp Med. 218:. PubMed
  28. Koikawa K, et al. 2021. Cell. 184:4753. PubMed
  29. Shiozawa S, et al. 2022. iScience. 25:103537. PubMed
  30. Mandal RK, et al. 2021. Cell Reports. 35(6):109094. PubMed
  31. Gong N, et al. 2020. Nat Nanotechnol. 1.35625. PubMed
  32. Onishi M, et al. 2015. J Immunol. 194:2673. PubMed
  33. Wedekind MF, et al. 2021. iScience. 24(7):102759. PubMed
  34. Zheng Y, et al. 2022. J Immunol. 208:501. PubMed
  35. Molina MS, et al. 2021. Front Immunol. 12:699128. PubMed
  36. Montalban-Arques A, et al. 2021. Cell Host Microbe. :. PubMed
  37. Si J, et al. 2020. Cancer Cell. 38(4):551-566.e11. PubMed
  38. Wagner AK, et al. 2022. iScience. 25:105137. PubMed
  39. Di Pilato M, et al. 2021. Cell. 184(17):4512-4530.e22. PubMed
  40. Shimba A et al. 2018. Immunity. 48(2):286-298 . PubMed
  41. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  42. Charlton J, et al. 2015. PLoS One. 10:119200. PubMed
  43. Yang FM, et al. 2022. Front Immunol. 13:918241. PubMed
  44. Li M, et al. 2020. J Immunother Cancer. 8:00. PubMed
RRID
AB_2251944 (BioLegend Cat. No. 135209)
AB_2159183 (BioLegend Cat. No. 135210)

Antigen Details

Structure
A 50-55 kD glycoprotein belonging to the CD28 family of the Ig superfamily.
Distribution

Induced on splenic T and B lymphocytes, thymocytes, and myeloid cells after stimulation.

Function
Involved in lymphocyte clonal selection and peripheral tolerance, prolonged survival of allografts.
Ligand/Receptor
B7-H1 (PD-L1) and B7-DC (PD-L2)
Cell Type
B cells, T cells
Biology Area
Cancer Biomarkers, Immunology, Inhibitory Molecules
Molecular Family
CD Molecules, Immune Checkpoint Receptors
Antigen References

1. Nishimura H, et al. 2001. Science 291:319
2. Agata Y, et al. 1996. Int. Immunol. 8:765
3. Liang SC, et al. 2003. Eur. J. Immunol. 33:2706
4. Barber DL, et al. 2006. Nature 439:682
5. Keir ME, et al. 2005. J. Immunol. 175:7372
6. Koehn BH. et al. 2008. J Immunol. 181:5313

Gene ID
18566 View all products for this Gene ID
UniProt
View information about CD279 on UniProt.org

Related FAQs

There are no FAQs for this product.
Go To Top Version: 2    Revision Date: 09.11.2014

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

  • PE anti-mouse CD279 (PD-1)

  • Purified anti-mouse CD279 (PD-1)

  • PerCP/Cyanine5.5 anti-mouse CD279 (PD-1)

  • APC anti-mouse CD279 (PD-1)

  • Biotin anti-mouse CD279 (PD-1)

  • FITC anti-mouse CD279 (PD-1)

  • PE/Cyanine7 anti-mouse CD279 (PD-1)

  • Brilliant Violet 421™ anti-mouse CD279 (PD-1)

  • Brilliant Violet 605™ anti-mouse CD279 (PD-1)

  • APC/Cyanine7 anti-mouse CD279 (PD-1)

  • Brilliant Violet 785™ anti-mouse CD279 (PD-1)

  • PE/Dazzle™ 594 anti-mouse CD279 (PD-1)

  • Alexa Fluor® 647 anti-mouse CD279 (PD-1)

  • Brilliant Violet 711™ anti-mouse CD279 (PD-1)

  • GoInVivo™ Purified anti-mouse CD279 (PD-1)

  • APC/Fire™ 750 anti-mouse CD279 (PD-1)

  • Brilliant Violet 510™ anti-mouse CD279 (PD-1)

  • Ultra-LEAF™ Purified anti-mouse CD279 (PD-1)

  • APC/Fire™ 810 anti-mouse CD279 (PD-1) Antibody

  • PE/Fire™ 810 anti-mouse CD279 (PD-1) Antibody

  • PE/Cyanine5 anti-mouse CD279 (PD-1)

  • PE/Fire™ 640 anti-mouse CD279 (PD-1)

  • Spark Red™ 718 anti-mouse CD279 (PD-1)

  • PerCP/Fire™ 806 anti-mouse CD279 (PD-1)

  • Brilliant Violet 750™ anti-mouse CD279 (PD-1)
ProductsHere
Login / Register
Remember me
Forgot your password? Reset password?
Create an Account